Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

201643 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Haematology

Volume 3, Issue 12, pp. e572-e580

Field-Weighted Citation Impact: 3.38